Pharmaceutical lobbying under postcommunism: Universal or country-specific methods of securing state drug reimbursement in Poland?

Health Economics, Policy and Law

Volumn 7, Issue 2, 2012, Pages 175-195

  Ozierański, Piotr ^a   McKee, Martin ^b   King, Lawrence ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DECISION MAKING; DRUG COST; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; EUROPE; FINANCIAL MANAGEMENT; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH CARE POLICY; HUMAN; IDEOLOGY; LEGAL PROCEDURE; PERSUASIVE COMMUNICATION; POLAND; POLITICS; PRIORITY JOURNAL; PUBLIC FIGURE; REIMBURSEMENT; RESOURCE ALLOCATION; REVIEW; SEMI STRUCTURED INTERVIEW;

COMMUNISM; COST-BENEFIT ANALYSIS; DRUG INDUSTRY; FINANCING, GOVERNMENT; GOVERNMENT AGENCIES; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; LOBBYING; MASS MEDIA; PATIENT PARTICIPATION; PERSUASIVE COMMUNICATION; POLAND; POLICY MAKING; POLITICS;

EID: 84857939913     PISSN: 17441331     EISSN: 1744134X     Source Type: Journal    
DOI: 10.1017/S1744133111000168     Document Type: Review

References (70)

1. Abraham, J. (2002), 'The pharmaceutical industry as a political player', The Lancet, 360: 1498-1502. (Pubitemid 35356330)
2. Abraham, J. (2009), 'Partial progress: Governing the pharmaceutical industry and the NHS, 1948-2008', Journal of Health Politics, Policy and Law, 34: 931-977.
3. Abraham, J. (2010), 'Pharmaceuticalization of society in context: Theoretical, empirical and health dimensions', Sociology, 44: 603-622.
4. Abraham, J. and G. Lewis (2000), Regulating medicines in Europe: Competition, expertise and public health, London: Routledge.
5. American Sociological Association,Code of ethics and policies and procedures of the ASA Committee of Professional Ethics, Washington,DC: American Sociological Association,1999.
6. American Sociological Association (1999), Code of ethics and policies and procedures of the ASA Committee of Professional Ethics, Washington, DC: American Sociological Association. Angell, M. (2005), The truth about drug companies. How they deceive us and what to do about it?, New York: Random House.
7. Baggot, R., J. Allsop and K. Jones (2005), Speaking for patients and carers. Health consumer groups and the policy process, Basingstoke: Palgrave.
8. Berrett, A., T. Roques, M. Small and R. D. Smith (2006), 'How much will Herceptin really cost?', British Medical Journal, 333: 1118.
9. Buckwell, C. (2008), 'Should the drug industry work with key opinion leaders? Yes', British Medical Journal, 336: 1404.
10. Burson-Marsteller, (2010), Acceso a los medicamentos, principal prioridad de la industria farmacéutica, 10 September, http://www.analitica.com/ noti-tips/6555712.asp [6 November 2010].
11. Choukroun, B. (2010), 'The swine flu epidemic: Compared analysis of the epidemic media coverage by French and British media', Lexis Nexis Analytics, October, http://www.lexisnexisanalytics.com/en/news/grippe-a.html [6 November 2010].
12. Cohen, D. and P. Carter (2010), 'Conflicts of interest. WHO and the pandemic flu ''conspiracies'' ', British Medical Journal, 340: C2912.
13. Conrad, P. (2007), The Medicalization of Society: On the Transformation of Human Conditions into Treatable Disorders, Baltimore, M.D.: Johns Hopkins University Press.
14. Fava, G. A. (2008), 'Should the drug industry work with key opinion leaders? No', British Medical Journal, 336: 1405.
15. Ferner, R. E. and S. E. McDowell (2006), 'How NICE may be outflanked', British Medical Journal, 332: 1268-1271. (Pubitemid 44365422)
16. García-Sempere, A. and J. J. Artell (2005), 'Organizació n, funcionamiento y expectativas de las organizaciones representativas de pacientes. Encuesta a informadores clave', Gaceta Sanitaria, 19(2): 120-126.
17. Geertz, C. (1973), 'Thick description: Toward an interpretive theory of culture', in C. Geertz (ed.), The Interpretation of Cultures: Selected Essays, New York: Basic Books, 3-30.
18. Grant, W. (2000), Pressure Groups and British Politics, London: MacMillan.
19. Hague, R. and M. Harrop (1992), Comparative government and politics: An introduction (3rd revised edition), Basingstoke: Macmillan.
20. Health Committee (2005), The Influence of the Pharmaceutical Industry. Fourth Report of Session 2004-2005, London: Stationery Office.
21. Hemminki, E., H. K. Toiviainen and L. Vuorenkoski (2010), 'Co-operation between patient organisations and the drug industry in Finland', Social Science and Medicine, 70(8): 1171-1175.
22. Herxheimer, A. (2003), 'Relationships between the pharmaceutical industry and patients' organisations', British Medical Journal, 326: 1208-1210. (Pubitemid 36649062)
23. Hood, C. (2011), The blame game: Spin, bureaucracy and self-preservation in government, Princeton, N.J.: Princeton University Press.
24. IMS Health and Rynek Zdrowia (2010), 'Polska w czoówce rynków wschodzǎcych w farmacji'. Rynek Zdrowia, 21 April, http://www.rynekzdrowia.pl/Farmacja/Polska-wczolowce-rynkow-wschodzacych-w- farmacji,17503,6.html [14 September 2010].
25. Jakubiak, L. (2009a), 'Podawanie paliwizumabu wcześniakom: Nie ma zgodności co do oceny skuteczności', Rynek Zdrowia, 16 October, http://www.rynekzdrowia.pl/Farmacja/Podawanie-paliwizumabu-wczesniakom-nie-ma- zgodnosci-co-do-oceny-skutecznosci, 11816,6.html [15 September 2010].
26. Jakubiak, L. (2009b), 'Rynek leków kreuje korupcjogenne zachowania, trzeba wiȩc z tym walczyć', Rynek Zdrowia, 12 December, http://www.rynekzdrowia.pl/Prawo/Rynek-lekow-kreujekorupcjogenne- zachowania-trzeba-wiec-z-tym-walczyc,13764,2,1.html [10 November 2010].
27. Jones, K. (2008), 'In whose interest? Relationships between health consumer groups and the pharmaceutical industry in the UK', Sociology of Health and Illness, 30(6): 929-943.
28. Kent, A. (2007), 'Should patient groups accept money from drug companies? Yes', British Medical Journal, 334: 934.
29. Koprǐvová , H. (2007), 'Postavení farmaceutickyćh firem v českém zdravotním systemu', Diploma Thesis. Masarykova univerzita, Brno, http://is.muni.cz/th/76203/esf-m/ DPHelena-Koprivova-FINAL.pdf [6 November 2010].
30. Kvale, S. (1996), InterViews. An introduction to qualitative research interviewing, London, Thousand Oaks, New Delhi: SAGE Publications.
31. Lapiński M. 2005. Walka z sitwǎ Warszawa: Offsetowa Drukarnia Wydawnicza.
32. Ledeneva, A. V. (2006), How Russia really works? The informal practices that shaped Post-Soviet politics and business, Ithaca, NY: Cornell University Press.
33. Malinowski, B. (2002), Argonauts of theWestern Pacific: An account of native enterprise and adventure in The Archipelagoes of Melanesian New Guinea, London and New York: Routledge.
34. Meyer, G. (ed.) (2006) Formal institutions and informal politics in Central and Eastern Europe. Hungary, Poland, Russia and Ukraine, Opladen and Farmington Hills: Barbara Budrich Publishers.
35. Ministerstwo Zdrowia (2004), Polityka lekowa państwa 2004-2008, Warszawa: Ministerstwo Zdrowia.
36. Ministerstwo Zdrowia (2005), Strategia rozwoju ochrony zdrowia w Polce na lata 2007-13. Dokument przyj?ety przez RM w dniu 21 czerwca 2005 r,Warszawa:Ministerstwo Zdrowia.
37. Mintzes, B. (2007), 'Should patient groups accept money from drug companies? No.', British Medical Journal, 334: 935.
38. Money.Pl,SN: Deszczyński ma być przeproszony za tekst ''Leki za miliony dolarów'''. Money.pl, 13 April,.2007,http://www.money. pl/archiwum/wiadomosci-agencyjne/pap/artykul/sn;deszczynski;ma;byc;przeproszony; za;tekst;leki;za;miliony;dolarow,20,0, 235796.html [24 September 2010].
39. Moynihan, R. (2003), 'Who pays for the pizzǎ Redefining the relationships between doctors and drug companies. 1: Entanglement', British Medical Journal, 326: 1189-1192. (Pubitemid 36649056)
40. Moynihan, R. (2008), 'Key opinion leaders. Independent experts or drug representatives in disguise?', British Medical Journal, 336: 1402-1403. (Pubitemid 351946976)
41. Moynihan, R., I. Heath and D. Henry (2003), 'Selling sickness: The pharmaceutical industry and disease mongering', British Medical Journal, 324: 886-891.
42. Nicoll, A. and M. McKee (2010), 'Moderate pandemic, not many dead -learning the right lessons in Europe from the 2009 pandemic', European Journal of Public Health, 20(5): 486-488.
43. Najwyzšza Izba Kontroli (2004), Informacja o wynikach kontroli funkcjonowania systemu tworzenia wykazu leków refundowanych.
44. Najwyzšza Izba Kontroli (2007), Wystǎpienie pokontrolne -Samodzielny Publicznym Szpitalu Klinicznym nr 5 Ślaškiego Uniwersytetu Medycznego.
45. Najwyzšza Izba Kontroli (2009), Wystǎpienie pokontrolne -Zespó ! Opieki Zdrowotnej w Końskich (ZOZ).
46. Narodowy Fundusz Zdrowia (2006), Sprawozdanie z dzia!alności Narodowego Funduszu Zdrowia za 2005 rok, Warszawa: Narodowy Fundusz Zdrowia.
47. Narodowy Fundusz Zdrowia (2007), Sprawozdanie z dzia!alności Narodowego Funduszu Zdrowia za 2006 rok, Warszawa: Narodowy Fundusz Zdrowia.
48. Narodowy Fundusz Zdrowia (2008), Sprawozdanie z dzia!alności Narodowego Funduszu Zdrowia za 2007 rok, Warszawa: Narodowy Fundusz Zdrowia.
49. Narodowy Fundusz Zdrowia (2009), Sprawozdanie z dzia!alności Narodowego Funduszu Zdrowia za 2008 rok, Warszawa: Narodowy Fundusz Zdrowia.
50. Narodowy Fundusz Zdrowia (2010a), Sprawozdanie z dzia!alności Narodowego Funduszu Zdrowia za 2009 rok, Warszawa: Narodowy Fundusz Zdrowia.
51. Narodowy Fundusz Zdrowia (2010b), Zmiana planu finansowego Narodowego Funduszu Zdrowia na 2010 r. zatwierdzona przez Ministra Zdrowia w porozumieniu z Ministrem Finansów w dniu 6 lipca 2010 r, Warszawa: Narodowy Fundusz Zdrowia.
52. OECD (2011), Consumer prices (MEI): Consumer prices -annual inflation, http://stats.oecd. org/Index.aspx [22 April 2011].
53. Oldani, M. J. (2004), 'Thick prescriptions: Toward an interpretation of pharmaceutical sales practices', Medical Anthropology Quarterly, 18: 325-356. (Pubitemid 41277784)
54. Parliamentary Assembly of the Council of Europe (2010), Report, recommendation and resolution 24/06/2010. The handling of the H1N1 Pandemic: More transparency Needed, Strasbourg: Parliamentary Assembly of the Council of Europe.
55. Payet, M. (2010), 'Swine flu experts under the influence of laboratories. Le Parisien explores pharma links to WHO and French government,' (Translated by Carolyn Dunning) Le Parisien, 26 January, http://www.theflucase.com/index.php? option5 com-contentandview5articleandid52656%3Ale-parisien-explores-pharma- links-towho-and-french-govenrmentandcatid51%3Alatest-newsandItemid564andlang5fr [5 November 2010].
56. Peräkylä , A. (1997), 'Reliability and validity in research based on tapes and transcripts', in D. Silverman (ed.), Qualitative Research. Theory, Methods and Practice, London, Thousand Oaks, New Delhi: Sage Publications, 201-220.
57. Procedura (2009), Procedura przyjmowania klientów zewn?etrznych, Warszawa: Ministerstwo Zdrowia.
58. Rynek Zdrowia (2010), 'Coraz duzšza kolejka ch?etnych do poprawiania projektu ustawy refundacyjnej', 18 October, http://www.rynekzdrowia. pl/Farmacja/Coraz-dluzszakolejka-chetnych-do-poprawiania-projektu-ustawy- refundacyjnej,102783,6.html [10 November 2010].
59. Silverman, D. (1993), Interpreting qualitative data. Methods for analysing talk, text and interaction, London: Sage Publications.
60. Sismondo, S. (2008), 'How pharmaceutical industry funding affects trial outcomes: Causal structures and responses', Social Science & Medicine, 66: 1909-1914. (Pubitemid 351454041)
61. Solska, J. (2009), 'Zakadnicy', Polityka 21 February.
62. Spielmans, G. I. and P. I. Parry (2010), 'From evidence-based medicine to marketing-based medicine: Evidence from internal industry documents', Journal of Bioethical Inquiry, 7(1): 13-29.
63. Strauss, A. L. (2001), Qualitative analysis for social scientists, Cambridge: Cambridge University Press.
64. The Lancet (2005), 'Herceptin and early breast cancer: A moment for caution', The Lancet, 366(9498): 1673.
65. Tiedemann, A. (2009), EU market access teams: New instruments to tackle non-tariff barriers to trade, Bruges: College of Europe.
66. Traufetter, G. (2009), 'German government flu expert advising pharma ''lobby group'' ', Spiegel Online International, 28 October, http://www.spiegel.de/international/germany/0,1518,657910,00.html [5 November 2010].
67. Ustawa, Ustawa z dnia 6 listopada 2008 r. o konsultantach w ochronie zdrowia, Dz.U. Dz.U. 2009, nr 52 poz.419.2009.
68. Vuorenkoski, L., H. Toiviainen and E. Hemminki (2003), 'Drug reimbursement in Finland: The case of explicit prioritising in special categories', Health Policy, 66(2): 169-177. (Pubitemid 37329738)
69. Wilson, P. M., A. M. Booth, A. Eastwood and I. S. Watt (2008), Deconstructing media coverage of trastuzumab (Herceptin): An analysis of national newspaper coverage', Journal of the Royal Society of Medicine, 101(3): 125-132. (Pubitemid 351570666)
70. Zarzycki, T., (2010), 'Firmy farmaceutyczne muszǎ dostosować si?e do zmian prawnych', Rynek Zdrowia, 23 April, http://www.rynekzdrowia.pl/Farmacja/Firmy-farmaceutyczne-muszadostosowac-sie-do- zmian-prawnych,17592,6.html [15 June 2010].